Nab-paclitaxel and trastuzumab combination: a promising approach for neoadjuvant treatment in HER2-positive breast cancer

被引：3

作者：

Ricciardi, Giuseppina Rosaria Rita

Franchina, Tindara

Russo, Alessandro

Schifano, Silvia

Ferraro, Giuseppa

Adamo, Vincenzo ^{[1
]}

机构：

[1] AO Papardo, Med Oncol Unit, I-98158 Messina, Italy

来源：

ONCOTARGETS AND THERAPY | 2016年 / 9卷

关键词：

breast cancer; HER2-positive; nab-paclitaxel; trastuzumab; neoadjuvant therapy; pathologic complete response; ALBUMIN-BOUND PACLITAXEL; RANDOMIZED PHASE-3 TRIAL; ADJUVANT CHEMOTHERAPY; PLUS TRASTUZUMAB; OPEN-LABEL; LAPATINIB; THERAPY; WOMEN; CYCLOPHOSPHAMIDE; MULTICENTER;

D O I：

10.2147/OTT.S107930

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Neoadjuvant therapy is a well-established approach for the treatment of locally advanced or inflammatory breast cancer (BC) and has been increasingly used in recent years not only as a management strategy but also as a research tool. Recently, nanoparticle albumin-bound paclitaxel (nab-paclitaxel)/trastuzumab combinations have been associated with promising activity in different clinical settings. In the present case, we report a complete pathological response after neoadjuvant treatment with the trastuzumab/nab-paclitaxel combination in a locally advanced human epidermal growth factor receptor 2 (HER2)-positive BC patient, with a good toxicity profile. This combination may represent a valid therapeutic option in the neoadjuvant therapy for HER2-positive locally advanced BC.

引用

页码：4351 / 4355

页数：5

共 27 条

[1] Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial [J].

Baselga, Jose ;

Bradbury, Ian ;

Eidtmann, Holger ;

Di Cosimo, Serena ;

de Azambuja, Evandro ;

Aura, Claudia ;

Gomez, Henry ;

Dinh, Phuong ;

Fauria, Karine ;

Van Dooren, Veerle ;

Aktan, Gursel ;

Goldhirsch, Aron ;

Chang, Tsai-Wang ;

Horvath, Zsolt ;

Coccia-Portugal, Maria ;

Domont, Julien ;

Tseng, Ling-Min ;

Kunz, Georg ;

Sohn, Joo Hyuk ;

Semiglazov, Vladimir ;

Lerzo, Guillermo ;

Palacova, Marketa ;

Probachai, Volodymyr ;

Pusztai, Lajos ;

Untch, Michael ;

Gelber, Richard D. ;

Piccart-Gebhart, Martine .

LANCET, 2012, 379 (9816) :633-640

[2] Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: Results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer [J].

Buzdar, AU ;

Ibrahim, NK ;

Francis, D ;

Booser, DJ ;

Thomas, ES ;

Theriault, RL ;

Pusztai, L ;

Green, MC ;

Arun, BK ;

Giordano, SH ;

Cristofanilli, M ;

Frye, DK ;

Smith, TL ;

Hunt, KK ;

Singletary, SE ;

Sahin, AA ;

Ewer, MS ;

Buchholz, TA ;

Berry, D ;

Hortobagyi, GN .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) :3676-3685

[3] Phase II Trial of Weekly Nanoparticle Albumin-Bound Paclitaxel With Carboplatin and Trastuzumab as First-line Therapy for Women With HER2-Overexpressing Metastatic Breast Cancer [J].

Conlin, Alison K. ;

Seidman, Andrew D. ;

Bach, Ariadne ;

Lake, Diana ;

Dickler, Maura ;

D'Andrea, Gabriella ;

Traina, Tiffany ;

Danso, Michael ;

Brufsky, Adam M. ;

Saleh, Mansoor ;

Clawson, Alicia ;

Hudis, Clifford A. .

CLINICAL BREAST CANCER, 2010, 10 (04) :281-287

[4] Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis [J].

Cortazar, Patricia ;

Zhang, Lijun ;

Untch, Michael ;

Mehta, Keyur ;

Costantino, Joseph P. ;

Wolmark, Norman ;

Bonnefoi, Herve ;

Cameron, David ;

Gianni, Luca ;

Valagussa, Pinuccia ;

Swain, Sandra M. ;

Prowell, Tatiana ;

Loibl, Sibylle ;

Wickerham, D. Lawrence ;

Bogaerts, Jan ;

Baselga, Jose ;

Perou, Charles ;

Blumenthal, Gideon ;

Blohmer, Jens ;

Mamounas, Eleftherios P. ;

Bergh, Jonas ;

Semiglazov, Vladimir ;

Justice, Robert ;

Eidtmann, Holger ;

Paik, Soonmyung ;

Piccart, Martine ;

Sridhara, Rajeshwari ;

Fasching, Peter A. ;

Slaets, Leen ;

Tang, Shenghui ;

Gerber, Bernd ;

Geyer, Charles E., Jr. ;

Pazdur, Richard ;

Ditsch, Nina ;

Rastogi, Priya ;

Eiermann, Wolfgang ;

von Minckwitz, Gunter .

LANCET, 2014, 384 (9938) :164-172

[5] Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial [J].

Gianni, Luca ;

Pienkowski, Tadeusz ;

Im, Young-Hyuck ;

Roman, Laslo ;

Tseng, Ling-Ming ;

Liu, Mei-Ching ;

Lluch, Ana ;

Staroslawska, Elzbieta ;

de la Haba-Rodriguez, Juan ;

Im, Seock-Ah ;

Pedrini, Jose Luiz ;

Poirier, Brigitte ;

Morandi, Paolo ;

Semiglazov, Vladimir ;

Srimuninnimit, Vichien ;

Bianchi, Giulia ;

Szado, Tania ;

Ratnayake, Jayantha ;

Ross, Graham ;

Valagussa, Pinuccia .

LANCET ONCOLOGY, 2012, 13 (01) :25-32

[6] Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort [J].

Gianni, Luca ;

Eiermann, Wolfgang ;

Semiglazov, Vladimir ;

Manikhas, Alexey ;

Lluch, Ana ;

Tjulandin, Sergey ;

Zambetti, Milvia ;

Vazquez, Federico ;

Byakhow, Mikhail ;

Lichinitser, Mikhail ;

Angel Climent, Miguel ;

Ciruelos, Eva ;

Ojeda, Belen ;

Mansutti, Mauro ;

Bozhok, Alla ;

Baronio, Roberta ;

Feyereislova, Andrea ;

Barton, Claire ;

Valagussa, Pinuccia ;

Baselga, Jose .

LANCET, 2010, 375 (9712) :377-384

[7] Preoperative Chemotherapy Plus Trastuzumab, Lapatinib, or Both in Human Epidermal Growth Factor Receptor 2-Positive Operable Breast Cancer: Results of the Randomized Phase II CHER-LOB Study [J].

Guarneri, Valentina ;

Frassoldati, Antonio ;

Bottini, Alberto ;

Cagossi, Katia ;

Bisagni, Giancarlo ;

Sarti, Samanta ;

Ravaioli, Alberto ;

Cavanna, Luigi ;

Giardina, Giovanni ;

Musolino, Antonino ;

Untch, Michael ;

Orlando, Laura ;

Artioli, Fabrizio ;

Boni, Corrado ;

Generali, Daniele Giulio ;

Serra, Patrizia ;

Bagnalasta, Michela ;

Marini, Luca ;

Piacentini, Federico ;

D'Amico, Roberto ;

Conte, PierFranco .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (16) :1989-1995

[8] Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer [J].

Joensuu, H ;

Kellokumpu-Lehtinen, P ;

Bono, P ;

Alanko, T ;

Kataja, V ;

Asola, R ;

Utriainen, T ;

Kokko, R ;

Hemminki, A ;

Tarkkanen, M ;

Turpeenniemi-Hujanen, T ;

Jyrkkiö, S ;

Flander, M ;

Helle, L ;

Ingalsuo, S ;

Johansson, K ;

Jääskeläinen, A ;

Pajunen, M ;

Rauhala, M ;

Kaleva-Kerola, J ;

Salminen, T ;

Leinonen, M ;

Elomaa, I ;

Isola, J .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (08) :809-820

[9] Pilot neoadjuvant trial in HER2 positive breast cancer with combination of nab-paclitaxel and lapatinib [J].

Kaklamani, Virginia G. ;

Siziopikou, Kalliopi ;

Scholtens, Denise ;

Lacouture, Mario ;

Gordon, Jennifer ;

Uthe, Regina ;

Meservey, Caitlin ;

Hansen, Nora ;

Khan, Seema A. ;

Jeruss, Jacqueline S. ;

Bethke, Kevin ;

Cianfrocca, Mary ;

Rosen, Steven ;

Von Roenn, Jamie ;

Wayne, Jeffrey ;

Parimi, Vamsi ;

Jovanovic, Borko ;

Gradishar, William .

BREAST CANCER RESEARCH AND TREATMENT, 2012, 132 (03) :833-842

[10] Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: Results from NSABP B-28 [J].

Mamounas, EP ;

Bryant, J ;

Leinbersky, B ;

Fehrenbacher, L ;

Sedlacek, SM ;

Fisher, B ;

Wickerham, DL ;

Yothers, G ;

Soran, A ;

Wolmark, N .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) :3686-3696

← 1 2 3 →